论文部分内容阅读
本文研究了黄芪柴胡复方注射液对慢性活动性乙型肝炎的临床效果及免疫调节作用。结果表明①IHCCo可明显改善CAH—B患者的临床症状。IHCCo治疗组与肝炎灵(GYL)对照组治疗后谷丙转氨酶(ALT)复常时间分别为31.30±10.3(n=15)与40.5±9.6(n=15)天(P<0.05)。②IRCCo组、GYL组HBeAg阴转数分别为9/14、2/12(P<0.05)。③IHCCo组及GYL组治疗后白细胞介素2(IL—2)活性分别为7.7±13.5(n=15)与4.59±3.21(n=15)×10~4cpm(P<0.05)。④IHCCo组与GYL组治疗后ALT复常时NK活性分别为0.29±0.06和0.30±0.06(P>0.05,但是IHCCo组有7例患者ALT复常1个月后复查了NK活性为0.39±0.07(P<0.05)。但是IHCCo组有7例患者ALT复常1个月后复查了NK活性为0.39±0.07(P<0.05)。这些结果提示黄芪柴胡复方注射液可能是治疗乙型病毒性肝炎较有前途的药物。
This article studied the clinical efficacy and immunoregulatory effect of Huangqi Chaihu compound injection on chronic active hepatitis B. The results showed that 1IHCCo can significantly improve the clinical symptoms of CAH-B patients. The duration of alanine aminotransferase (ALT) after treatment in the IHCCo treatment group and the GYL control group was 31.30±10.3 (n=15) and 40.5±9.6 (n=15) days, respectively (P<0.05). 2The number of HBeAg negative in IRCCo and GYL groups was 9/14 and 2/12 respectively (P<0.05). The IL-2 activity in 3IHCCo and GYL groups was 7.7±13.5 (n=15) and 4.59±3.21 (n=15)×10-4 cpm, respectively (P<0.05). 4The ALT complex NK activity in the IHCCo and GYL groups was 0.29±0.06 and 0.30±0.06, respectively (P>0.05, but the NK activity in the IHCCo group was 7 months after the ALT complex was 0.39±0.07. P<0.05).However, 7 patients in the IHCCo group had NK activity of 0.39±0.07 (P<0.05) after one month of ALT revival. These results suggest that Huangqi Chaihu compound injection may be a treatment for hepatitis B virus More promising drugs.